Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "Official" company response/non-response to 10q questions

"The acceptance of any such offer before the patent re-examinations and '584 Appeal results are known would be, in my very humble opinion, a total dereliction of fiduciary duty."

From our perspective, this was my initial thought as well. Still is,but what if it was a pretty much a straight up merger, without concessions from either side? (ie. no .80 etc. from TPL, no prefereds from us) Just a merging of the 2 co's. Wouldn't it then come down to who you felt was the more valuable company as to whether it was a good deal for shareholders?

In my mind, it's looked as if TPL was the more valuable with what they've aquired and ramped up. Tho with large expenses coming with that. What are your thoughts? joe

Share
New Message
Please login to post a reply